NPPA slashes prices of 390 cancer drugs; move to benefit 22 lakh patients

All companies have been asked to ensure that the price caps are adhered to.

The National Pharmaceutical Pricing Authority (NPPA) has slashed the prices of 390 cancer drugs by up to 87 per cent with immediate effect. 

This comes after the NPPA had capped the margins of 42 cancer drugs at 30 per cent recently. 

Now, 390 brands, which constitute 91 per cent of the 426 brands in the anti-cancer segment, are under price control. This move by the NPPA is expected to benefit 22 lakh cancer patients in the country and would result in an annual savings of approx Rs 800 crore to the consumer, the department of pharmaceuticals said in a statement. 

The government also